Author: claimsbot

1. A method for providing spectral containment over telecommunications service lines, comprising:
selecting a filter having spectral characteristics corresponding to a predetermined passband;
connecting the filter in series to and between two ends of at least one loop used to provide at least one telecommunications service to a customer; and
activating service over said at least one loop, said filter preventing signals transmitted on frequencies outside of the predetermined passband over said at least one loop.
2. The method according to claim 1,
wherein said prevented signals comprise unexpected transmissions.
3. The method according to claim 1,
wherein said prevented signals comprise unauthorized transmissions.
4. The method according to claim 1,
wherein said prevented signals comprise unintended transmissions.
5. The method according to claim 1, said connecting further comprising:
housing the filter within a housing that also houses a loop modification unit.
6. The method according to claim 1, said connecting further comprising:
placing the filter within a spectrum protector coil that interfaces with a housing that houses a loop modification unit.
7. The method according to claim 1, said connecting further comprising:
connecting the filter in series to at least one loop of a loop plant, said filter intervening between a remote terminal facility and copper pair side of the loop.
8. The method according to claim 1, said selecting further comprising:
determining a service to be excluded on said at least one loop from the group consisting of DDS, ISDN, and xDSL; and
selecting a filter having spectral characteristics excluding operating frequencies of the determined service.
9. A method for manufacturing a spectral containment unit for providing spectral containment over telecommunications service lines, comprising:
selecting a filter having predetermined spectral characteristics corresponding to a predetermined passband;
connecting the filter in series to and between two ends of at least one loop used to provide at least one telecommunications service to a customer; and
packaging said filter within a housing that also houses a loop modification unit.
10. The method according to claim 9, said selecting further comprising:
determining a service to be excluded by said filter from the group consisting of DDS, ISDN, and xDSL; and
selecting a filter having spectral characteristics excluding operating frequencies of the determined service.
11. A method for manufacturing a spectral containment unit for providing spectral containment over telecommunications service lines, comprising:
selecting a filter having predetermined spectral characteristics corresponding to a predetermined passband;
connecting the filter in series to and between two ends of at least one loop used to provide at least one telecommunications service to a customer; and
packaging said filter within a spectrum protector coil that interfaces with a housing that houses a loop modification unit filter.
12. The method according to claim 11, said selecting further comprising:
determining a service to be excluded by said filter from the group consisting of DDS, ISDN, and xDSL; and
selecting a filter having spectral characteristics excluding operating frequencies of the determined service.
13. An apparatus for providing spectral containment over telecommunications service lines, comprising:
a filter having spectral characteristics corresponding to a predetermined passband, the filter being connected in series to and between two ends of at least one loop used to provide at least one telecommunications service to a customer, said filter preventing signals transmitted on frequencies outside of the predetermined passband over said at least one loop.
14. The apparatus according to claim 13,
wherein said prevented signals comprise unexpected transmissions.
15. The apparatus according to claim 13,
wherein said prevented signals comprise unauthorized transmissions.
16. The apparatus according to claim 13,
wherein said prevented signals comprise unintended transmissions.
17. The apparatus according to claim 13, further comprising:
a housing that houses said filter and a loop modification unit.
18. The apparatus according to claim 13, further comprising:
a spectrum protector coil within which the filter is provided, and which interfaces with a housing that houses a loop modification unit.
19. The apparatus according to claim 13,
wherein said filter is connected in series to at least one loop of a loop plant, said filter intervening between a remote terminal facility and copper pair side of the loop.
20. The apparatus according to claim 13, said filter excluding transmissions selected from the group of services consisting of: DDS, ISDN, and xDSL.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method for treating a mental health disorder and improving workplace productivity and disability reduction related to said disorders comprising the steps of:
(a) having a patient access an interactive website for an initial visit;
(b) having the patient answer one or more screening questions to determine whether there is a possibility of the patient having a mental health disorder;
(c) processing the patient’s answers to the one or more screening questions to determine whether there is the possibility of the patient having a mental health disorder;
(d) where there is the possibility of the patient having a mental health disorder, selecting a module of diagnostic risk assessment questions related to a specific mental health disorder;
(e) having the patient answer the diagnostic risk assessment questions related to the specific mental health disorder;
(f) processing the patient’s answers to the diagnostic risk assessment questions to determine the level of risk for a particular diagnosis;
(g) providing the patient with a preliminary diagnostic risk assessment map which comprises a list of the patient’s answers to the screening questions and the diagnostic risk assessment questions, and provides the level of risk for a particular diagnosis;
(h) providing the patient with a CARE MAP which comprises evidence-based instructions for patients and physicians on possible treatments;
(i) providing the patient with a follow-up map which comprises data on symptom and functional impairment severity trends over time, absenteeism, presenteeism, and medical and personal history of the patient, as provided by the patient;
(j) having the patient share the preliminary diagnostic risk assessment map, the CARE MAP and the follow-up map with a physician in printable form or via electronic records;
(k) after considering the preliminary diagnostic risk map, the CARE MAP and the follow-up map, the physician instituting medical treatment of the patient;
(l) providing the patient with a follow-up reminder via the internet andor telephone to access the interactive website for a return visit;
(m) having the patient access the website for the return visit;
(n) having the patient answer the diagnostic risk questions from step (e) again;
(o) having the patient answer questions regarding management history of the medical treatment; and
(p) processing the patient’s answers to the questions from steps (n) and (o) to determine whether there should be a change in the medical treatment of the patient.
2. The method according to claim 1, wherein the patient accesses the website anonymously.
3. The method according to claim 2, wherein the patient is provided with a user I.D. and password for accessing the website.
4. The method according to claim 1, further comprising the step of having the patient answer demographic questions.
5. The method according to claim 1, wherein the specific mental health disorder is selected from the group consisting of depression, bipolar disorder, post traumatic stress disorder, generalized anxiety disorder, panic anxiety disorder, obsessive-compulsive disorder, alcohol dependency, substance abuse, and eating disorders.
6. The method according to claim 1, wherein the website provides the patient with a physician’s letter comprising a description of the purpose of the website and an overview of the website’s credentials.
7. The method according to claim 1, wherein the follow-up reminder is provided three weeks after the patient’s initial visit.
8. The method according to claim 1, wherein the website provides hyperlinks to literature on the clinical andor medical science of mental health disorders.
9. The method according to claim 1, wherein said patients are employees andor members of disability or health insurance plans.
10. The method according to claim 9, wherein the method is used in combination with an employee assistance program.
11. A system for treating mental health disorders and improving workplace productivity and disability reduction related to said disorders, wherein said system comprises an interactive website, said website comprising:
(a) a web page for accessing the web site;
(b) a screening questionnaire for determining whether there is a possibility of a patient having a mental health disorder;
(c) means for processing the answers to the screening questionnaire to determine whether there is the possibility of the patient having a mental health disorder;
(d) a diagnostic questionnaire for determining the patient’s level of risk for a particular diagnosis;
(e) means for processing the answers to the diagnostic questionnaire to determine the patient’s level of risk for a particular diagnosis;
(f) means for providing a preliminary diagnostic risk assessment map which comprises a list of the patient’s answers to the screening questionnaire and the diagnostic risk assessment questionnaire, and provides the level of risk for a particular diagnosis;
(g) means for providing a CARE MAP which comprises evidence-based instructions for patients and physicians on possible treatments;
(h) means for providing a follow-up map which comprises data on symptomfunctional impairment trends over time, and medical and personal history of the patient, as provided by the patient; and
(i) following medical treatment, means for providing a follow-up reminder via the Web andor phone to the patient to access the website for a return visit.
12. The system according to claim 11, wherein the system provides means for the patient to access the website anonymously.
13. The system according to claim 11, wherein the website further comprises means for providing a physician’s letter describing the purpose of the website and providing an overview of the website’s credentials.
14. The system according to claim 11, wherein the website further comprises hyperlinks to literature on the clinical andor medical science of mental health disorders.
15. A method for providing aggregate economic information to the employerinsurer regarding productivity losses due to mental disorders, most effective medical interventions in terms of restoration of productivity level and reduction of disability and aggregate information to public and private health insurers on most effective medical interventions that limit morbidity and mortality and promote early remission and recovery, said method comprising:
(a) having a patient access an interactive website for an initial visit;
(b) having the patient answer one or more screening questions to determine whether there is a possibility of the patient having a mental health disorder;
(c) processing the patient’s answers to the one or more screening questions to determine whether there is the possibility of the patient having a mental health disorder;
(d) where there is the possibility of the patient having a mental health disorder, selecting a module of diagnostic risk assessment questions related to a specific mental health disorder;
(e) having the patient answer the diagnostic risk assessment questions related to the specific mental health disorder;
(f) processing the patient’s answers to the diagnostic risk assessment questions to determine the level of risk for a particular diagnosis;
(g) providing the patient with a preliminary diagnostic risk assessment map which comprises a list of the patient’s answers to the screening questions and the diagnostic risk assessment questions, and provides the level of risk for a particular diagnosis;
(h) providing the patient with a CARE MAP which comprises evidence-based instructions for patients and physicians on possible treatments;
(i) providing the patient with a follow-up map which comprises data on symptom and functional impairment severity trends over time, and medical and personal history of the patient, as provided by the patient;
(j) having the patient share the preliminary diagnostic risk assessment map, the CARE MAP and the follow-up map with a physician in printable form or via electronic records;
(k) after considering the preliminary diagnostic risk map, the CARE MAP and. the follow-up map, the physician instituting medical treatment of the patient;
(l) providing the patient with a follow-up reminder via the internet andor telephone to access the interactive website for a return visit;
(m) having the patient access the website for the return visit;
(n) having the patient answer the diagnostic risk questions from step (e) again;
(o) having the patient answer questions regarding management history of the medical treatment;
(p) processing the patient’s answers to the questions from steps (n) and (o) to determine whether there should be a change in the medical treatment of the patient; and
(q) having the patient answer questions about job classification, days absent, salary per day, days present but having percent productivity loss, days with symptoms, days of treatment (type and dosage), said data collected allowing correlation between clinical status, treatment, and workplace costs and savings (clinical economic correlation);
(r) processing data from (q) using analytical tools to derive clinico-economic information; and
(s) reporting to an entity arranging for access to the website with aggregate information regarding the value of workplace economic loss and benefit of the method.
16. The method according to claim 8, wherein said literature includes information on medical treatments for mental health disorders and the risks associated with terminating the medical treatments early.
17. The system according to claim 14, wherein said literature includes information on medical treatments for mental health disorders and the risks associated with terminating the medical treatments early.

1. An adjunct for retrofitting to an oximetry sensor to improve at least one of useful life, restored adhesion integrity, and patient tolerance thereof, comprising:
an adhesive patient contact layer, wherein a first side of the adhesive patient contact layer is configured to attach to a patient’s skin and a second side of the adhesive patient contact layer is configured to attach to an oximetry sensor, directly or through an intermediate layer; and
a photo-opaque layer for application over the oximetry sensor.
2. The adjunct of claim 1, wherein the adhesive patient contact layer is configured to transmit energy from an energy-emitting component and to an energy-detecting component of the oximetry sensor.
3. The adjunct of claim 1, wherein the adhesive patient contact layer has at least one aperture therein, such that when retrofitted to the oximetry sensor the aperture is aligned with at least one of an energy-emitting component and an energy-detecting component of the oximetry sensor to facilitate energy from the energy-emitting component or energy to the energy-detecting component passing through the aperture.
4. The adjunct of claim 1, wherein the adhesive patient contact layer comprises a hydrocolloid.
5. The adjunct of claim 4, wherein the hydrocolloid adhesive patient contact layer has a thickness of 10 to 30 mil.
6. The adjunct of claim 3, wherein the adhesive patient contact layer comprises a hydrocolloid.
7. The adjunct of claim 6, wherein the hydrocolloid adhesive patient contact layer has a thickness of 10 to 30 mil.
8. The adjunct of claim 1, wherein the photo-opaque layer comprises polyethylene terephthalate (PET).
9. The adjunct of claim 1, further comprising at least one intermediate layer between the adhesive patient contact layer and the oximetry sensor.
10. The adjunct of claim 9, further comprising two intermediate layers between the adhesive patient contact layer and the oximetry sensor, a barrier layer in direct contact with the adhesive patient contact layer, and a double-sided adhesive layer in direct contact with the oximetry sensor.
11. The adjunct of claim 10, wherein the intermediate barrier layer comprises polypropylene.
12. The adjunct of claim 11, wherein the intermediate barrier layer has a thickness of 1 to 2 mil.
13. The adjunct of claim 9, further comprising a label liner layer above the intermediate layer and a liner layer below the adhesive patient contact layer, wherein the liner layer is removed in order to attach the adhesive patient contact layer to a patient’s skin and the label liner layer is removed in order to attach the intermediate layer to the oximetry sensor.
14. The adjunct of claim 2, wherein the energy-emitting component of the oximetry sensor is selected from the group consisting of: a near infrared spectrum light emitting diode and a near infrared spectrum light emitting optode.
15. The adjunct of claim 2, wherein the energy-detecting component of the oximetry sensor is selected from the group consisting of: a near infrared spectrum photodiode and a near infrared spectrum photo-optode.
16. A dispensing roll comprising a plurality of sheets along the roll, the plurality of sheets being separated from each other by perforations that permit one sheet to be removed from adjacent sheets, each sheet of said plurality of sheets having the adjunct of claim 1 disposed thereon.
17. The dispensing roll of claim 16, wherein the adjunct is disposed on each sheet in two sections, a first section comprising the adhesive patient contact layer and a second section comprising the photo-opaque layer, or in one section comprising the adhesive patient contact layer or the photo-opaque layer.
18. A method for improving at least one of useful life, restored adhesion integrity, and patient tolerance of an oximetry sensor and reducing replacement cost thereof, comprising:
applying an adhesive patient contact layer to a skin surface of a patient, the adhesive patient contact layer being separate from an oximetry sensor;
applying the oximetry sensor above the adhesive patient contact layer, directly or indirectly through intermediate layers; and
applying a photo-opaque layer over the oximetry sensor.
19. The method of claim 18, further comprising sensing oxygen saturation with the oximetry sensor through the adhesive patient contact layer.
20. An oximetry sensor comprising:
an adhesive patient contact layer comprising a hydrocolloid;
a photo-opaque layer; and
an energy-emitting component and an energy-detecting component, the energy-emitting component and the energy-detecting component both positioned between the hydrocolloid adhesive patient contact layer and the photo-opaque layer.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method for the synthesis of 1,3-di(chloropropyl)-5-tert-butyl benzene comprising:
conducting Friedl-Crafts alkylation of 1,3-diisopropylbenzene by tert-butyl chloride in the presence of an alkylation catalyst to obtain 1-tert-butyl-3,5-diisopropylbenzene;
peroxidizing the 1-tert-butyl-3,5-diisopropylbenzene by gaseous oxygen in the presence of a peroxidation catalyst in a basic solution to obtain 1,3-di(peroxypropyl)-5-tert-butylbenzene;
reducing the 1,3-di(peroxypropyl)-5-tert-butylbenzene with a reducing agent to 1,3-di(hydroxypropyl)-5-tert-butylbenzene; and
chlorinating the 1,3-di(hydroxpropyl)-5-tert-butylbenzene to obtain 1,3-di(chloropropyl)-5-tert-butyl benzene.
2. The method according to claim 1, wherein the alkylation catalyst is an Iron(III) salt, such as, for example, FeCl3.
3. The method according to claim 1, wherein said peroxidation catalyst in the basic solution is a Cobalt(II) salt and a tertiary amine in water.
4. The method according to claim 3, wherein the Colbalt(II) salt is CoCl2 and the tertiary amine is pyridine.
5. The method according to claim 1, wherein the step of peroxidizing further includes the steps of:
adjusting a pH of the 1,3-di(peroxypropyl)-5-tert-butylbenzene in solution with the addition of a base solution to a pH=10; and
extracting the water phase with ether to provide a mixture containing 1,3-di(peroxypropyl)-5-tert-butylbenzene dissolved in ether.
6. The method according to claim 1, wherein the reducing agent is sodium sulfite.
7. The method according to claim 5, wherein the step of reducing includes reducing the mixture with sodium sulfite to provide 1,3-di(hydroxypropyl)-5-tert-butylbenzene,
separating and extracting the water with additional ether; and
evaporating and drying the 1,3-di(hydroxypropyl)-5-tert-butylbenzene.
8. The method according to claim 7, wherein the step of reducing further includes washing with hexane and recrystallizing with ethyl acetate the 1,3-di(hydroxpropyl)-5-tert-butylbenzene.
9. The method according to claims 1 wherein the step of chlorinating includes dissolving 1,3-di(hydroxypropyl)-5-tert-butylbenzene in methyl chloride to provide a solution and bubbling the solution in HCl
10. The method according to claim 1, wherein the step of chlorinating includes purifying the 1,3-di(chloropropyl)-5-tert-butyl benzene by evaporating and recrystallizing the 1,3-di(chloropropyl)-5-tert-butyl benzene in hexane.
11. A composition of 1-tert-butyl-3,5-diisopropylbenzene.
12. A composition of 1,3-di(chloropropyl)-5-tert-butyl benzene made from the method of claim 1.
13. (canceled)
14. (canceled)